NCT00627627 - A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2010

Conditions

Breast Cancer

Interventions

DRUG

IPI-504

dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle

Trial Locations (7)

Georgetown Univ Medical Cntr, Lombardi Comprehensive Cancer Center,, Washington D.C.

"Duke University Med Cntr Breast Oncology Research Program", Durham

Low County Hen/Onc, Mt. Pleasant

Lynn Regional Cancer - West Campus, Boca Raton

Medical Specialists of the Palm Beaches, Lake Worth

University Hospitals Case Medical Center, Cleveland

Cleveland Clinic Medical Center, Cleveland